2
|
Cashman KA, Wilkinson ER, Shaia CI, Facemire PR, Bell TM, Bearss JJ, Shamblin JD, Wollen SE, Broderick KE, Sardesai NY, Schmaljohn CS. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. Hum Vaccin Immunother 2017; 13:2902-2911. [PMID: 29045192 PMCID: PMC5718832 DOI: 10.1080/21645515.2017.1356500] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Lassa virus (LASV) is an ambisense RNA virus in the Arenaviridae family and is the etiological agent of Lassa fever, a severe hemorrhagic disease endemic to West and Central Africa.1,2 There are no US Food and Drug Administration (FDA)-licensed vaccines available to prevent Lassa fever.1,2 in our previous studies, we developed a gene-optimized DNA vaccine that encodes the glycoprotein precursor gene of LASV (Josiah strain) and demonstrated that 3 vaccinations accompanied by dermal electroporation protected guinea pigs from LASV-associated illness and death. Here, we describe an initial efficacy experiment in cynomolgus macaque nonhuman primates (NHPs) in which we followed an identical 3-dose vaccine schedule that was successful in guinea pigs, and a follow-on experiment in which we used an accelerated vaccination strategy consisting of 2 administrations, spaced 4 weeks apart. In both studies, all of the LASV DNA-vaccinated NHPs survived challenge and none of them had measureable, sustained viremia or displayed weight loss or other disease signs post-exposure. Three of 10 mock-vaccinates survived exposure to LASV, but all of them became acutely ill post-exposure and remained chronically ill to the study end point (45 d post-exposure). Two of the 3 survivors experienced sensorineural hearing loss (described elsewhere). These results clearly demonstrate that the LASV DNA vaccine combined with dermal electroporation is a highly effective candidate for eventual use in humans.
Collapse
Affiliation(s)
- Kathleen A Cashman
- a Virology Division, United States Army Medical Research Institute of Infectious diseases (USAMRIID) , Fort Detrick , MD , USA
| | - Eric R Wilkinson
- a Virology Division, United States Army Medical Research Institute of Infectious diseases (USAMRIID) , Fort Detrick , MD , USA
| | - Carl I Shaia
- b Pathology Division, United States Army Medical Research Institute of Infectious diseases (USAMRIID) , Fort Detrick , MD , USA
| | - Paul R Facemire
- b Pathology Division, United States Army Medical Research Institute of Infectious diseases (USAMRIID) , Fort Detrick , MD , USA
| | - Todd M Bell
- b Pathology Division, United States Army Medical Research Institute of Infectious diseases (USAMRIID) , Fort Detrick , MD , USA
| | - Jeremy J Bearss
- b Pathology Division, United States Army Medical Research Institute of Infectious diseases (USAMRIID) , Fort Detrick , MD , USA
| | - Joshua D Shamblin
- a Virology Division, United States Army Medical Research Institute of Infectious diseases (USAMRIID) , Fort Detrick , MD , USA
| | - Suzanne E Wollen
- a Virology Division, United States Army Medical Research Institute of Infectious diseases (USAMRIID) , Fort Detrick , MD , USA
| | | | | | - Connie S Schmaljohn
- d Office of the Chief Scientists, Headquarters, United States Army Medical Research Institute of Infectious Diseases , Fort Detrick , MD , USA
| |
Collapse
|
3
|
Le Pogam C, Patel S, Gorombei P, Guerenne L, Krief P, Omidvar N, Tekin N, Bernasconi E, Sicre F, Schlageter MH, Chopin M, Noguera ME, West R, Abu A, Mathews V, Pla M, Fenaux P, Chomienne C, Padua RA. DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies. Oncotarget 2015; 6:32494-508. [PMID: 26378812 PMCID: PMC4741708 DOI: 10.18632/oncotarget.5572] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2015] [Accepted: 08/14/2015] [Indexed: 02/06/2023] Open
Abstract
We have previously shown that a specific promyelocytic leukemia-retinoic acid receptor alpha (PML-RARA) DNA vaccine combined with all-trans retinoic acid (ATRA) increases the number of long term survivors with enhanced immune responses in a mouse model of acute promyelocytic leukemia (APL). This study reports the efficacy of a non-specific DNA vaccine, pVAX14Flipper (pVAX14), in both APL and high risk myelodysplastic syndrome (HR-MDS) models. PVAX14 is comprised of novel immunogenic DNA sequences inserted into the pVAX1 therapeutic plasmid. APL mice treated with pVAX14 combined with ATRA had increased survival comparable to that obtained with a specific PML-RARA vaccine. Moreover, the survival advantage correlated with decreased PML-RARA transcript levels and increase in anti-RARA antibody production. In HR-MDS mice, pVAX14 significantly improved survival and reduced biomarkers of leukemic transformation such as phosphorylated mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) 1. In both preclinical models, pVAX14 vaccine significantly increased interferon gamma (IFNγ) production, memory T-cells (memT), reduced the number of colony forming units (CFU) and increased expression of the adapter molecule signalling to NF-κB, MyD88. These results demonstrate the adjuvant properties of pVAX14 providing thus new approaches to improve clinical outcome in two different models of myeloid malignancies, which may have potential for a broader applicability in other cancers.
Collapse
Affiliation(s)
- Carole Le Pogam
- Unité Mixte de la Recherche de Santé (UMR-S), Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.,Institut National de la Santé et de la Recherche Médicale (INSERM) Unité (U), Paris, France
| | - Satyananda Patel
- Unité Mixte de la Recherche de Santé (UMR-S), Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.,Institut National de la Santé et de la Recherche Médicale (INSERM) Unité (U), Paris, France
| | - Petra Gorombei
- Unité Mixte de la Recherche de Santé (UMR-S), Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.,Institut National de la Santé et de la Recherche Médicale (INSERM) Unité (U), Paris, France
| | - Laura Guerenne
- Unité Mixte de la Recherche de Santé (UMR-S), Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.,Institut National de la Santé et de la Recherche Médicale (INSERM) Unité (U), Paris, France
| | - Patricia Krief
- Unité Mixte de la Recherche de Santé (UMR-S), Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.,Institut National de la Santé et de la Recherche Médicale (INSERM) Unité (U), Paris, France
| | - Nader Omidvar
- Haemotology Department, Cardiff University School of Medicine, Cardiff, UK
| | - Nilgun Tekin
- Biotechnology Institute, Ankara University, Ankara, Turkey
| | - Elena Bernasconi
- Unité Mixte de la Recherche de Santé (UMR-S), Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.,Institut National de la Santé et de la Recherche Médicale (INSERM) Unité (U), Paris, France
| | - Flore Sicre
- Unité Mixte de la Recherche de Santé (UMR-S), Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.,Institut National de la Santé et de la Recherche Médicale (INSERM) Unité (U), Paris, France.,Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Marie-Helene Schlageter
- Unité Mixte de la Recherche de Santé (UMR-S), Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.,Institut National de la Santé et de la Recherche Médicale (INSERM) Unité (U), Paris, France.,Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Martine Chopin
- Département d'Expérimentation Animale, Institut Universitaire d'Hématologie, University Paris Diderot, Paris, France
| | - Maria-Elena Noguera
- Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Robert West
- Welsh Heart Research Institute, Cardiff University School of Medicine, Cardiff, UK
| | - Ansu Abu
- Department of Hematology, Christian Medical College and Hospital, Vellore, India
| | - Vikram Mathews
- Department of Hematology, Christian Medical College and Hospital, Vellore, India
| | - Marika Pla
- Unité Mixte de la Recherche de Santé (UMR-S), Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.,Institut National de la Santé et de la Recherche Médicale (INSERM) Unité (U), Paris, France
| | - Pierre Fenaux
- Unité Mixte de la Recherche de Santé (UMR-S), Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.,Institut National de la Santé et de la Recherche Médicale (INSERM) Unité (U), Paris, France.,Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Christine Chomienne
- Unité Mixte de la Recherche de Santé (UMR-S), Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.,Institut National de la Santé et de la Recherche Médicale (INSERM) Unité (U), Paris, France.,Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Rose Ann Padua
- Unité Mixte de la Recherche de Santé (UMR-S), Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.,Institut National de la Santé et de la Recherche Médicale (INSERM) Unité (U), Paris, France.,Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| |
Collapse
|